Why Provectus Biopharmaceuticals Is Giving Away Its Most Valuable Molecule — On Purpose
A guide to Veripure™️, the open science program built around our pharmaceutical grade rose bengal sodium API.
The Counterintuitive Move
On June 25, 2026, Provectus launched Veripure™️, which is a program that gives qualified medical researchers, anywhere in the world, free access (via a Material Transfer Agreement) to the same pharmaceutical grade rose bengal sodium (RBS) active pharmaceutical ingredient (API) used in the Company’s clinical trials. No fee. No direction on what to study. No restriction on what they conclude.
Why it matters
A clinical-stage biotech trying to commercialize a drug just handed the core material away to anyone qualified to ask for it, with no strings attached. That’s not how most companies treat the asset they’re betting the farm on. The question worth answering before deciding whether this is smart or reckless: what is Provectus giving up and what is it getting back?
The material going out the door is the real thing, not a diluted version, not a commercial-grade substitute, but the identical pharma-grade API used in Provectus’s clinical trials.
Researchers in the U.S., Canada, Australia, and France already have worked with it.
The Company’s own language is unambiguous: no constraints on study direction, design, or findings.
That’s the surface. To judge whether it’s a good trade, you need to know what’s actually in the box, and why anyone would want it badly enough to ask.
What Veripure Actually Is
Veripure isn’t a new relationship. It’s a name, a structure, and a quality benchmark put around relationships that, in several cases, already existed. Provectus has supplied PV-10, formulated from its pharmaceutical grade RBS API, to independent researchers studying oncology, dermatology, hematology, ophthalmology, infectious disease, wound healing, and tissue repair in sponsored and non-sponsored settings well before the Veripure brand existed.
Why it matters
The institutional roster is the easiest part of this story to verify and the easiest part to overstate. It’s real, but it’s not new output. It’s existing scientific infrastructure now organized under a single name.
The list includes MD Anderson, Moffitt Cancer Center, The Rockefeller University, Bascom Palmer Eye Institute, the NIH Center for Interventional Oncology, a leading pediatric cancer research hospital (identified here only to the extent the Material Transfer Agreement permits), the University of Calgary, University of Saskatchewan, two Australian universities, and the University of Lille.
Veripure launched in June 2026. There is no Veripure-branded publication or finding yet; there hasn’t been time. What exists today is the relationship infrastructure the brand now sits on top of.
Some of Provectus’s most consequential recent patents trace back to independent scientific inquiry that was sponsored but not formally run under the Veripure name or its structure. Veripure is, in part, a public commitment to keep doing, at greater scale and with a name attached, what was already working.
That distinction matters for judging the program honestly: is Veripure starting a new engine, or putting a hood ornament on one that was already running? The honest answer is closer to the second, which is a reasonable thing for a shareholder to want, but not the same claim as “look at this new thing we built.”
The Quality Argument: Why “Free” Doesn’t Mean “Cheap”
Provectus’s case for giving away pharmaceutical grade material rests on a specific claim: that the commercially sourced rose bengal material most academic labs use is inconsistent and, in some cases, contaminated, and that inconsistency quietly undermines a lot of the existing rose bengal literature.
Why it matters
If this is true, Veripure isn’t generosity. It’s quality control disguised as a giveaway, and it explains why the Company believes it can afford to do this at scale.
Rose bengal as a molecule dates back to 1882. Commercial grade material sold by specialty chemical suppliers is, by Provectus’s account, still largely produced using the original 19th-century process or variants of it.
In 2022, Provectus worked with a U.S.-headquartered and based contract manufacturer to test commercial grade rose bengal lots against its own pharmaceutical grade RBS. Every commercial lot tested showed purity that diverged from what was stated on its certificate of analysis, and one lot contained gross contaminants its certificate didn’t disclose.
That study was internal and unpublished, although referenced in the Company’s SEC filings on Form 10-K and 10-Q. It’s a real data point, but it’s also Provectus grading its own competition with no independent verification. It is worth saying plainly, because a skeptical reader will notice the gap if we don’t.
If the purity gap is real, and Provectus believes it is, the strategic logic gets much more interesting than “we’re being generous.” It explains why the Company would want this specific material — not just any rose bengal — driving the next wave of research.
The Strategic Logic: Buying Validation That You Can’t Actually Buy
Here’s the case for Veripure as a deliberate strategy rather than a leap of faith: independent researchers, working from their own questions, in diseases Provectus didn’t pick, reaching findings that converge with what the Company already believes about RBS. That is a stronger signal than another sponsored trial, and it costs a fraction as much.
Why it matters
Sponsored research always carries a credibility discount, because the sponsor picked the question and funded the answer. Findings from researchers Provectus didn’t direct and doesn’t control carry less of that discount, if they happen.
A sponsored trial can cost millions or tens of millions of dollars, and tests one hypothesis the company chose. Veripure can test many more hypotheses other people chose, for the marginal cost of manufacturing a few hundred dollars’ worth of API per vial. That is a cost that’s de minimis against Provectus’s existing manufacturing infrastructure, which is already built and paid for.
The institutions in the program span multiple distinct disease categories. Trying to run and manage multiple internal tests of whether RBS’s underlying biology does indeed span multiple diseases would likely come at a cost no single biotechnology company could justify directly funding.
The upside isn’t guaranteed and it is not fast. Independent academic research moves on its own timeline, publishes on its own schedule, and answers the questions the investigator finds interesting, not necessarily the ones that move a stock price.
That asymmetry — low cost, parallel testing, real but uncertain payoff — is the heart of the bull case. It’s also exactly the kind of asymmetry a skeptic will want to stress-test.
The Bear Case: What This Program Doesn’t Guarantee
A fair accounting of Veripure must include what can go wrong, because a program built on “no restrictions” cuts both ways.
Why it matters
Shareholders weighing Veripure’s upside should weigh these risks at the same time, not after the fact.
A negative or unflattering finding becomes public with Provectus’s name attached, on someone else’s timeline. The Company doesn’t control what gets published or when. An independent lab finding that RBS doesn’t work in their disease, or works less impressively than hoped, is now part of the public record associated with Provectus’s flagship open-science initiative.
“Open science” can read as a tacit admission to skeptical investors. The implicit story some will tell is “a small OTCQB company can’t fund its own pivotal trials, so it’s outsourcing discovery to whoever will take free material.” That’s not necessarily true, but it’s a real perception risk the Company is taking on.
There’s no output yet. Veripure launched a week or so ago. Every institution named in the announcement predates the program. The actual test of whether this generates anything new — publications, findings, innovation, partnerships — has not started.
The one long-running, large-scale clinical test of RBS in a single indication didn’t reach a result. Provectus’s historical Phase 3 trial of intralesional PV-10 in locally advanced cutaneous melanoma was terminated because the trial’s enrollment assumptions (of prior Company leadership) overestimated how many patients with the targeted disease stage (in-transit melanoma, which is a very small subset of Stage IIIB–IVM1a melanoma) existed to enroll. Provectus doesn’t yet have a completed late-stage readout to point to as proof the platform can ultimately convert into at least one approved medicine, and hopefully more.
None of these risks are disqualifying. But a post that only lists upside isn’t analysis, it is marketing. We continue to build additional moats — filing and prosecuting new patents as the science generates them — which can mitigate, though not eliminate, these risks. Shareholders deserve the full picture for their decision-making.
And because that package is already built and paid for, Provectus retains the option to compete on price against any commodity-grade challenger — a lever a would-be competitor building from zero would not have.
Why Give Away Probably Valuable Material? The Moat Isn’t Just the Molecule
This is the question worth sitting with longest: if independent researchers figure out that RBS solves their disease, what does Provectus keep?
Why it matters
The authentic answer is that the molecule itself was never the defensible asset and understanding why changes what kind of company this is.
Rose bengal has been a known compound since 1882. Composition-of-matter protection on the molecule itself is not available to anyone, Provectus included. Any lab could, in principle, chase the same biological question using commercial grade material without Provectus in the room at all (and many have, as represented by publications in the broader rose bengal literature). The open-science bet is not risking a secret, because there isn’t one.
What’s actually proprietary sits downstream of any single discovery. It is the patented and trade-secreted commercial-scale manufacturing process for pharmaceutical grade RBS API, the chemistry-manufacturing-control (CMC) specifications built over years, the multi-lot stability data of both API and drug product candidate PV-10, and the regulatory acceptance trail across FDA, BfArM, TGA, ANSM, AIFA, COFEPRIS, and ANMAT. A lab that proves RBS works in a new disease still cannot bring a drug to market without reproducible, regulator-accepted manufacturing, which Provectus believes it is the only one to have currently built.
The realistic vulnerability is not “they steal the finding;” it’s “a well-funded competitor decides to invent around the molecule entirely.” A large pharmaceutical company could see a promising independent result and choose to develop a structurally adjacent compound rather than work with Provectus. That’s a real risk for any platform built on an old, unpatentable molecule, and Provectus does not currently have structure-activity data proving that close chemical relatives lose the relevant biology. This risk should be stated as a real one.
What blunts that risk isn’t secrecy, it is time and cost. Inventing around RBS still means years and a large multiple of capital spent rebuilding the toxicology, manufacturing, and clinical package Provectus has already accumulated, from zero. A rational competitor weighing that cost against partnering with the Company that already has the regulatory file may not find inventing around it worth doing. But “may not find it worth doing” is a probability, not a guarantee, and shareholders should treat it as such.
That’s a more modest claim than “we are protected.” It is also a more credible one and it’s the actual answer to what happens when someone outside Provectus figures out RBS solves their problem.
The GSK Playbook — and Where Provectus’s Bet Is Riskier
Open science in biopharma isn’t a new idea. The closest large-scale precedent is GSK’s Published Kinase Inhibitor Set (PKIS). The comparison is instructive precisely because of where it breaks down.
Why it matters
Precedent tells us the open-science model can generate real scientific output at scale. It also tells us Provectus is taking on more risk than GSK did.
Between 2011 and 2017, GSK and a successor academic consortium distributed 367 kinase inhibitor compounds to more than 300 laboratories, with one condition: results had to be released into the public domain.
The output was real: new chemical leads for previously untargeted kinases, funded grant applications, publications, and, in at least one documented case, a new selective inhibitor developed from a compound in the original set. The program later expanded to include compounds from multiple pharmaceutical companies, not just GSK.
Here’s the part that does not translate cleanly: GSK’s shared compounds had already been published and disclosed before release. There was no live IP at stake; they had nothing left to lose by giving them away. Provectus is doing the opposite: handing out its core, still-proprietary API while it is still trying to commercialize medicines built on it.
What Shareholders Should Track
The debate above is theoretical until there’s data. Here’s what would move it from theory to evidence, in order of how soon you’ll be able to check it.
Why it matters
Veripure is new. What to watch for:
New institutions joining the program, beyond the roster that predates the Veripure brand. Growth here signals real demand, not just a rebrand of existing relationships.
Publications or conference abstracts that specifically credit Veripure-supplied material, the first concrete output distinguishable from Provectus’s pre-existing sponsored research.
Any finding that results in a new patent filing in an indication the Company wasn’t already pursuing.
Any partnership, licensing conversation, or collaboration that traces back to a Veripure relationship rather than a pre-existing sponsored one.
The Bottom Line
Veripure is a bet that external validation, generated inexpensively and in parallel across many diseases, is worth more to Provectus than the limited IP exposure and optics risk of giving away its core material with few conditions attached. The molecule itself was never defensible; that’s just a chemical structure. What’s defensible is the manufacturing, the regulatory trail, and the time it would take any competitor to rebuild either from scratch.
All of this rests on our conviction that the underlying biology is real — a conviction the clinical work and independent research are still testing, not a settled fact. If it holds, Veripure lets us pressure-test that biology across diseases we couldn't reach on our own, and faster than traditional drug discovery would permit.
That is a real argument, not a marketing line. It’s also unproven. The institutional roster behind Veripure existed before the brand did. The brand’s actual test — new findings, new patents, new partnerships traceable specifically to the program — starts now. Shareholders should treat this announcement as the opening of that test.
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) is a clinical-stage biotechnology company developing a pipeline of immunotherapy medicines based on rose bengal sodium (RBS), a first-in-class synthetic small molecule from the halogenated xanthene family. The Company’s clinical programs span oncology, dermatology, and ophthalmology, with additional proof-of-concept programs in hematology, wound healing, infectious diseases, and tissue repair. This post reflects management’s current views on RBS, Veripure, and Provectus’s competitive position. It is not investment advice. Forward-looking statements are subject to the risks described in Provectus’s filings with the SEC, including its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Forward-Looking Statements
The information provided in this Provectus Substack Post may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this Provectus Substack Post are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of Provectus’s:
Annual Report on Form 10-K for the period ended December 31, 2025, and
Quarterly Report on Form 10-Q for the period ended March 31, 2026.